Canton Strategic Holdings (CNTN) Research & Development (2021 - 2026)
Canton Strategic Holdings (CNTN) reported Research & Development of $267823.0 for Q1 2026, down 54.92% on a YoY basis from $594070.0 in Q1 2025, and down 83.83% quarter-over-quarter from $1.7 million in Q4 2025.
Canton Strategic Holdings (CNTN) Research & Development (2021 - 2026) Analysis & Trends
Canton Strategic Holdings has reported Research & Development for 6 years, with the latest figure at $267823.0 in Q1 2026.
- For the quarter ending Q1 2026, Research & Development fell 54.92% year-over-year to $267823.0; the trailing twelve-month figure through Mar 2026 stood at $2.7 million (down 53.9% YoY), and the FY2025 full-year result was $3.1 million, down 51.91% from the prior year.
- Research & Development for Q1 2026 stood at $267823.0, down from $1.7 million in the prior quarter.
- The five-year high for Research & Development was $2.3 million in Q3 2024, with the low at $267823.0 in Q1 2026.
- Historically, Research & Development has averaged $915996.6 across 5 years, with a median of $831844.0 in 2022.
- Annual changes were most pronounced in 2022 — Research & Development soared 1766.15% — and 2025, when it sank 87.83%.
- Canton Strategic Holdings' Research & Development stood at $683205.0 in 2022, then soared by 45.3% to $992725.0 in 2023, then jumped by 110.07% to $2.1 million in 2024, then declined by 20.6% to $1.7 million in 2025, then slumped by 83.83% to $267823.0 in 2026.
- The last three Research & Development figures came in at $267823.0 (Q1 2026), $1.7 million (Q4 2025), and $277803.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -2.30 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 1.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -58.00 Mn |
| 10 | Canton Strategic Holdings | 699.97 Mn | 658.44 Mn | - | 267,823.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 267,823.00 |
| Dec 31, 2025 | 1.66 Mn |
| Sep 30, 2025 | 277,803.00 |
| Jun 30, 2025 | 546,204.00 |
| Mar 31, 2025 | 594,070.00 |
| Dec 31, 2024 | 2.09 Mn |
| Sep 30, 2024 | 2.28 Mn |
| Jun 30, 2024 | 999,553.00 |
| Mar 31, 2024 | 1.03 Mn |
| Dec 31, 2023 | 992,725.00 |
| Sep 30, 2023 | 488,177.00 |
| Jun 30, 2023 | 1.03 Mn |
| Mar 31, 2023 | 1.05 Mn |
| Dec 31, 2022 | 683,205.00 |
| Sep 30, 2022 | 831,844.00 |
| Jun 30, 2022 | 455,546.00 |
| Mar 31, 2022 | 307,829.00 |
| Dec 31, 2021 | -41,005.00 |
| Sep 30, 2021 | 313,133.00 |
| Jun 30, 2021 | 674,765.00 |